Current Edition

cancer drugs

Merck, Roche and J&J among pharma players weighing Russian operations amid humanitarian tightrope walk

You can’t buy a Coke, Frappuccino or Big Mac in Russia anymore, but cancer patients may still be able to get Merck’s megablockbuster Keytruda. While …

Continue Reading →

As Russian invasion persists, Roche, Teva, Novartis, Merck and more make renewed push to support besieged Ukraine

As Ukraine holds the line against the Russian invasion, pharma majors are making a renewed push to adjust operations in the region and supply the …

Continue Reading →

CMS’ Biogen decision could spell problems for Lilly, Roche Alzheimer’s drugs, half of surveyed neurologists say

Neurologists in the U.S. are agreeing with a new draft decision from the Centers for Medicare & Medicaid Services (CMS) that restricts reimbursement of Biogen’s …

Continue Reading →

Roche’s aim to widen Evrysdi’s label nabs speedy FDA review in young spinal muscular atrophy patients

Now poised for a speedy trip through the FDA’s regulatory review, Roche’s oral challenger in spinal muscular atrophy (SMA) could soon pick up a nod …

Continue Reading →
antibody drug conjugates

ASH: Roche’s Polivy set to unlock $2B market in newly diagnosed lymphoma with practice-changing data

The guessing is over. Roche has detailed new Polivy data that could change nearly two decades of treatment standards in newly diagnosed lymphoma—while opening up …

Continue Reading →

For pharmas dealing with HCPs, the future is digital first—and sales reps 2nd

While many people are suffering from Zoom fatigue and looking forward to in-person meetups, that isn’t really the case when it comes to HCPs and …

Continue Reading →

Bristol Myers Squibb’s Opdivo posts another win in early lung cancer, but debate over treatment approach likely remains

Bristol Myers Squibb has expanded Opdivo’s first-in-class win in pre-surgery non-small cell lung cancer, teeing up a potential FDA filing. Opdivo added to chemotherapy before …

Continue Reading →

Roche ushers early lung cancer into immunotherapy era with Tecentriq FDA approval. Will doctors follow?

Roche’s Tecentriq has ushered in a new era, offering the first immunotherapy option for non-small cell lung cancer (NSCLC) patients right after tumour surgery. But …

Continue Reading →

Citing ‘less-than-optimal’ outcomes for Roche’s Evrysdi, Biogen launches high-dose Spinraza trial

While much of the attention on Biogen lately has centred on its launch of controversial Alzheimer’s disease drug Aduhelm, the company is also feeling the …

Continue Reading →

Roche’s Polivy to hit $2.4B as doctors expect ‘significant switching’ in newly diagnosed lymphoma: analyst

Roche Pharmaceuticals CEO Bill Anderson recently pegged lymphoma drug Polivy’s potential expansion into newly diagnosed patients as a multibillion-dollar opportunity. Now, at least one analyst …

Continue Reading →